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Abstract
‘‘Ecstasy’’ (3,4-methylenedioxymethamphetamine, MDMA) has been shown to be hepatotoxic for human users, but molecular
mechanisms involved in this effect remained poorly understood. MDMA-induced cell damage is related to programmed cell death in
serotonergic and dopaminergic neurons. However, until now there has been no evidence of apoptosis induced by MDMA in liver cells. Here
we demonstrate that exposure to MDMA caused apoptosis of freshly isolated rat hepatocytes and of a cell line of hepatic stellate cells (HSC),
as shown by chromatin condensation of the nuclei and accumulation of oligonucleosomal fragments in the cytoplasm. In both cell types,
apoptosis correlated with decreased levels of bcl-xL, release of cytochrome c from the mitochondria and activation of caspase 3. In HSC, but
not in hepatocytes, MDMA induced poly(ADP-ribose)polymerase (PARP) proteolysis. These results suggest that apoptosis of liver cells
could be involved in the hepatotoxicity of MDMA.
D 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
3,4-Methylenedioxymethamphetamine (MDMA, ‘‘Ecs-
tasy’’) is a derivative of amphetamine that has become
extensively used as a recreational drug. Although MDMA
has been popularly considered as a safe drug, there are
increasing evidences of its toxicity. MDMA is neurotoxic
for serotonergic and dopaminergic neurons and produces a
decrease of 5-HT transporters [1,2]. Other side-effects of
MDMA are hyperthermia, rhabdomyolysis and cardiac
dysrhythmias [3,4]. Severe liver injury and hepatitis in
the presence or absence of systemic features have also
been described in MDMA users. MDMA hepatotoxicity is
idiosyncratic and appears with different intensity, from
mild hepatitis that resolves spontaneously, to fulminant
liver failure requiring liver transplant. The latency is also
variable, raging from days to weeks after the intake [5–9].
Programmed cell death is probably involved in the neuro-
toxic effects of MDMA, since MDMA induces apoptosis of
serotonergic and neocortical neurons [10,11] and immortal-
ized neuron cells [12] through regulation of proteins belong-
ing to the bcl-2 family. However, the underlying mechanisms
for the toxic effect of MDMA in liver cells are not fully
established yet. MDMA has been shown to produce a
decrease in the viability of freshly isolated hepatocytes [13]
and to induce collagen production in hepatic stellate cells
(HSC) [14]. To our knowledge, the possibility of MDMA
exerting an apoptotic effect in liver cells as a mechanism
involved in liver damage elicited by this drug, has not been
studied until now.
In the present study, the ability of MDMA to induce
programmed cell death of freshly isolated rat hepatocytes
and a cell line of HSC has been examined. MDMAwas found
to exert a pro-apoptotic effect in both cell types, as demon-
strated by biochemical and morphological parameters.
2. Materials and methods
2.1. Reagents
MDMA–HCl was a gift from the ‘‘Audiencia Provincial
de Navarra’’. Tumor necrosis factor a (TNF-a) was from
Boehringer Mannheim (Mannheim, Germany); Actinomycin
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D (ActD) was purchased from Sigma (St. Louis, MO); Ac-
DEVD-CHO, Hoechst 33342 and camptothecin were from
Calbiochem (La Jolla, CA). Cell culture reagents were from
Gibco BRL (Grand Island, NY). Poly(ADP-ribose)polymer-
ase (PARP), bcl-xL polyclonal rabbit and bax monoclonal
mouse antibodies were from Santa Cruz Biotechnologies
(Santa Cruz, CA). Cytochrome c monoclonal antibody was
from BD PharMingen.
2.2. Cell culture and treatments
The HSC cell line CFSC-2G [15] was used for some
experiments. Cells were cultured in minimum essential
medium (MEM) supplemented with 10% fetal bovine serum
(FBS) and nonessential amino acids for 36 h; after which the
medium was replaced with a serum-free medium. Treat-
ments were carried out 12 h later.
Freshly isolated hepatocytes were obtained by liver
collagenase perfusion from male Wistar rats as described
elsewhere [16]. Isolated hepatocytes were resuspended and
plated in MEM supplemented with 10% FBS and nones-
sential amino acids. Four hours after platting the cells the
medium was replaced by MEM supplemented with 1%
FBS, and treatments were carried out 12 h later.
Cells were treated with the indicated concentrations of
MDMA for 8 or 24 h. In some experiments hepatocytes
were treated with camptothecin (10 Ag/ml) or TNF-a
(10 ng/ml) for 8 h. Prior to the addition of TNF-a, cells
were sensitized by a 30-min pre-treatment with ActD
(15 ng/ml).
2.3. Nuclear staining
Cell nuclei were visualized using the DNA-binding
fluorochrome Hoechst 33342. Cells were fixed with meth-
anol for 8 min at  20 jC. After washing with PBS, the
cells were incubated at room temperature for 5 min with
Hoechst 33342 (0.5 Ag/ml), gently washed three times
with PBS, embedded in glycerol/PBS (1:1) and examined
under UV light on a fluorescence microscope Labophot-2
(Nikon).
2.4. Determination of oligonucleosomal (histone-associ-
ated) DNA fragments
The presence of soluble histone–DNA complexes, was
measured by the Cell Death Detection Assay (Boehringer
Mannheim). For this assay, HSC were seeded on 24-well
plates at a density of 80,000 cells/well and hepatocytes in
35-mm culture dishes at a density of 3 106 cells/dish. In
some cell cultures Ac-DEVD-CHO (0.1 mM) was added 3 h
before treating hepatocytes and HSC with 1.0 and 5.0 mM
MDMA, respectively. Cell death ELISA assays were per-
formed according to the manufacturer’s instructions. Spe-
cific enrichment of mono- and oligonucleosomes released
into the cytoplasm (enrichment factor, EF) was calculated as
the ratio between the absorbance values of the samples
obtained from treated and control cells.
2.5. Western blot
After treatment with MDMA, cells were washed with
PBS and whole-cell lysates were obtained. Equal amounts
of protein were size-fractionated by 10% (PARP) or 12%
(bcl-x and bax) sodium dodecylsulfate polyacrylamide gel
electrophoresis (SDS-PAGE) and electrotransfered to nitro-
cellulose membranes. The membranes were incubated with
anti-PARP, anti-bcl-x polyclonal rabbit or anti-bax mono-
clonal mouse antibodies, diluted 1:2000; and for 1 h with
either anti-rabbit immunoglobulin horseradish peroxidase
conjugate (Promega, Madison, WI) or anti-mouse immuno-
globulin horseradish peroxidase conjugate (Amersham
Pharmacia Biotech), diluted 1:4000. Bound antibodies were
detected by enhanced chemiluminiscence autoradiography
with ECL-Plus (Amersham Pharmacia Biotech). Equivalent
loading was confirmed by Coomasie staining of an identical
gel.
Cytochrome c was analyzed in cytosolic and mitochon-
drial fractions obtained by differential centrifugation in 250
mM sucrose buffer as described previously [17]. Five
micrograms of protein were subjected to 15% SDS-PAGE.
Membranes were exposed to mouse anti-cytochrome c
monoclonal antibody at a 1:1000 dilution, followed by
incubation with anti-mouse immunoglobulin horseradish
peroxidase conjugate at a 1:2000 dilution.
2.6. Measurement of caspase 3 activity
Caspase 3 activity was measured using the Caspase-3/
CPP32 Colorimetric Assay Kit (BioVision, Palo Alto, CA,
USA). Cells (3 106 hepatocytes or 2 106 HSC) were
scraped in culture medium, pelleted, resuspended in lysis
buffer and caspase 3 activity was measured following
manufacturer’s instructions.
2.7. Statistical analysis
The data were analyzed using the Kruskal–Wallis test to
determine differences between all independent groups.
When significant differences were obtained (P < 0.05), dif-
ferences between two groups were tested using the Mann–
Withney U test.
3. Results
3.1. MDMA induces morphological changes and chromatin
condensation in hepatocytes and HSC
The morphological effects of MDMA on hepatocytes
and HSC were first evaluated by light microscopy.
Hepatocytes exposed to 1.0 mM MDMA showed an
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altered morphology 8 h after treatment. As shown in Fig.
1B, MDMA-treated hepatocytes presented loss of mem-
brane differentiations and were highly refringent, as
compared to untreated cells. HSC required a longer
treatment (24 h) and a higher dose of MDMA (5.0
mM) to show morphological modifications. HSC acquired
a netlike disposition and cells became round-shaped and
refringent in response to MDMA treatment (Fig. 1D).
The concentrations of MDMA used were similar to those
described in toxicity studies carried out either in neurons
or hepatocytes [11,13].
In order to visualize the nuclei of the cells, prepara-
tions of hepatocytes and HSC were subjected to the same
treatments as above and stained with Hoechst 33342. In
both cell types, MDMA treatment resulted in chromatin
condensation and nuclear fragmentation (Fig. 1F and H),
alterations commonly associated with programmed cell
death [18].
3.2. Accumulation of oligonucleosomal fragments in the
cytoplasm of hepatocytes and HSC in response to MDMA
treatment
The cytoplasmic levels of DNA (histone-associated)
oligonucleosomal fragments in cells treated for 24 h with
different concentrations of MDMA were determined. The
presence of these fragments in the cytoplasm reflects the
extent of DNA fragmentation and nuclear disruption that are
characteristic of apoptosis [19].
Fig. 1. Morphology of hepatocytes and HSC after treatment with
MDMA. (A–D) Morphology by light microscopy of control and
MDMA-treated hepatocytes and HSC. Original magnification  200.
(E–H) Nuclear staining of hepatocytes and HSC using Hoechst 33342.
Arrowheads point to chromatin condensation and fragmented nuclei in
MDMA-treated cells. Original magnification  1000. (A, E) Control
hepatocytes. (B, F) Hepatocytes incubated for 8 h with 1.0 mM
MDMA. (C, G) Control HSC. (D, H) HSC incubated for 24 h with 5.0
mM MDMA.
Fig. 2. Determination of oligonucleosomal fragments in cytoplasmic
extracts from hepatocytes and HSC treated with MDMA. Hepatocytes
and HSC were treated for 24 h with the indicated concentrations of MDMA.
Oligonucleosomal fragments content was expressed as EF, as described in
Materials and methods. In some cell cultures Ac-DEVD-CHO was added
before treating hepatocytes and HSC with 1.0 and 5.0 mM MDMA,
respectively. Each bar represents the meanF S.D. of quadruplicate
determinations from at least two independent experiments. (A) EF of
hepatocytes treated with MDMA ( *P< 0.05, **P< 0.01, ***P< 0.001; a,
vs. control; b, vs. 1.0 mM MDMA). (B) EF of HSC treated with MDMA
( *P< 0.05, **P < 0.01; a, vs. control; b, vs. 5.0 mM MDMA).
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As shown in Fig. 2, values of two- to threefold increase
in the cytoplasmic content of oligonucleosomal fragments
were obtained in hepatocytes treated with 0.5 and 1.0 mM
MDMA, and three- to tenfold increase in HSC treated with
3.0 and 5.0 mM MDMA. In some experiments hepatocytes
were exposed to higher concentrations of MDMA (3.0 and
5.0 mM), but despite the fact that chromatin condensation
and nuclear fragmentation were observed, no significant
accumulation of oligonucleosomal fragments was detected
(data not shown). A post-apoptotic necrosis resulting in the
degradation of the histone–DNA complexes could explain
this finding.
The cytoplasmic accumulation of oligonucleosomal frag-
ments was diminished in both cell types by pre-treatment
with the inhibitor of the caspase 3 family Ac-DEVD-CHO
(Fig. 2), suggesting the involvement of caspases in the clea-
vage of DNA associated with MDMA-induced apoptosis.
3.3. Bcl-xL and bax protein levels in hepatocytes and HSC
treated with MDMA
Bcl-2 family members are proteins that modulate apop-
tosis mainly by controlling the release of pro-apoptotic
factors from the mitochondrial intermembrane to the cyto-
plasm [20]. These proteins are regulated by different molec-
ular mechanisms, including changes in protein levels
through transcriptional and post-transcriptional alterations.
Since MDMA has been shown to modify mRNA levels of
bcl-xL and bax in neurons [11], we studied if these proteins
were as well altered in liver cells exposed to the drug.
Protein levels of bcl-xL and bax were analyzed by
Western blot after treating the cells for 8 h with MDMA
at the previously tested concentrations (0.5 and 1.0 mM for
hepatocytes, and 3.0 and 5.0 mM for HSC). The anti-
apoptotic protein bcl-xL was decreased by MDMA treat-
ment both in hepatocytes and HSC. However, protein levels
of bax, a pro-apoptotic member of the bcl-2 protein family,
remained unchanged in both cell types after treatment with
MDMA (Fig. 3).
3.4. Cytochrome c release, caspase 3 activity and PARP
proteolysis in hepatocytes and HSC treated with MDMA
Cytochrome c release from the mitochondria has been
described as a central event in the stress-induced apoptotic
pathway [21]. Cytochrome c release leads to the activation
of downstream effector caspases, which cleave a number of
cellular proteins facilitating DNA fragmentation and cell
death [22]. We evaluated by Western blot the cytochrome c
levels in cytoplasmic and mitochondrial extracts obtained
from hepatocytes and HSC treated for 8 h with MDMA, at
the concentrations previously indicated. MDMA treatment
of both cell types resulted in increased cytosolic levels of
cytochrome c that correlated with decreased levels of the
protein in the mitochondria (Fig. 4). Since cytochrome c
release has been related to caspase 3 activation [23], we also
analyzed the activity of this enzyme in hepatocytes and HSC
exposed to MDMA as above, to evaluate its involvement in
MDMA-induced apoptosis. In both cell types, MDMA
Fig. 3. Western Blot analysis of bcl-xL and bax in MDMA-treated
hepatocytes and HSC. Hepatocytes and HSC were treated for 8 h with the
indicated concentrations of MDMA.
Fig. 4. Cytochrome c release from the mitochondria in MDMA-treated hepatocytes and HSC. Cells were treated for 8 h with the indicated concentrations of
MDMA and cytosolic and mitochondrial extracts obtained. Western blot analysis using a monoclonal cytochrome c antibody was performed in extracts from
hepatocytes (A) or HSC (B).
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caused a moderate but significant increase in caspase 3
activity, which was assessed using a commercial colorimet-
ric kit (Fig. 5).
PARP degradation by caspases is considered a biochem-
ical marker for the execution phase of the apoptotic
response [24]. PARP cleavage was evaluated in extracts
from MDMA-treated cells by the appearance of the 85-kDa
proteolytic fragment and the disappearance of the 116-kDa
intact PARP, both of them recognized by the same antibody.
As Fig. 6B shows, HSC presented an increased degradation
of PARP in response to treatment with 3.0 and 5.0 mM
MDMA for 8 h. On the contrary, MDMA treatment of
primary hepatocytes for 8 h did not result in an increased
degradation of PARP, as compared to samples obtained from
untreated cells. Two widely used apoptotic inducers, such as
camptothecin and ActD/TNF-a [25], also failed to enhance
PARP proteolysis in this cell type (Fig. 6A).
4. Discussion
Apoptosis is a highly regulated process involved in an
array of physiological and pathological responses, including
cell damage associated with toxic substances. In the liver,
apoptosis has been shown to be responsible for damage
induced by endotoxic shock [26], copper accumulation in
Wilson’s disease [27] and hypoxia/reoxigenation injury
[28]. Since MDMA had been described as a pro-apoptotic
agent for neurons [10–12], we sought to investigate whether
apoptosis of liver cells could contribute to the hepatotoxic
effect of this drug, focussing on two of the cell types present
in the liver, hepatocytes and HSC. MDMA was found to
exert a pro-apoptotic effect in both cell types, as determined
by morphological and biochemical alterations commonly
associated with programmed cell death, such as chromatin
condensation of the nuclei and accumulation of oligonu-
cleosomal fragments in the cytoplasm. The involvement of
caspases in the fragmentation of DNA induced by MDMA
was demonstrated by pre-treatment of both cell types with
the caspase 3 family inhibitor Ac-DEVD-CHO, which
significantly prevented the cytoplasmic accumulation of
oligonucleosomal fragments in both cell types. This inhib-
itory effect could be due to the participation of a caspase-
activated DNase [29] in the apoptotic action of MDMA.
Fig. 5. Caspase 3 activity in hepatocytes and HSC treated with MDMA.
Caspase 3 activity was assessed as described in Materials and methods,
using 150 Ag of protein extracts from hepatocytes (A) or HSC (B), treated
with the indicated concentrations of MDMA for 8 h. Activity is referred to
control, nontreated cells. Each bar represents the meanF S.D. of quad-
ruplicate determinations ( *P < 0.05 vs. control).
Fig. 6. Western Blot analysis of PARP in MDMA-treated hepatocytes and
HSC. Hepatocytes and HSC were exposed for 8 h to treatment with the
indicated concentrations of MDMA. Hepatocytes were also treated with
camptothecin and ActD/TNF-a, as described in Materials and methods.
Arrows indicate the 116-kDa band (intact PARP) and the 85-kDa band
(PARP proteolytic fragment) from hepatocytes (A) or HSC (B), treated with
the indicated apoptotic inducers.
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Previous data have shown that D-amphetamine, a drug
structurally related to MDMA, can increase apoptosis in
preneoplastic and neoplastic nodules in an animal model for
hepatocellular carcinoma [30]. However, as the authors
indicate, in these lesions liver cells are already undergoing
high constitutive apoptosis as a result of treatment with a
chemical agent, and are more sensitive to other substances.
Our data show that MDMA is an apoptotic inducer for
normal liver cells in the absence of other agents. This fact
could be related to the increasing reports of severe liver
damage caused by this particular derivative of amphet-
amine.
Proteins belonging to the bcl-2 family seem to play a key
role in the apoptotic response triggered by derivatives of
amphetamines. MDMA induces changes in the expression
of the splice variants of the bcl-x gene in neurons [11], D-
amphetamine increases basal apoptosis of neoplastic liver
lesions through dysregulation of bcl-2 family genes [30],
and an increased expression of bcl-2 can prevent apoptosis
of immortalized neuron cells induced by methamphetamine
[12]. Therefore, we sought to investigate whether alterations
in the expression of members of the bcl-2 family could also
be involved in the apoptotic effect of MDMA in normal
liver cells. We found a similar pattern of alterations in the
proteins obtained either from hepatocytes or HCS treated
with MDMA. The anti-apoptotic member of the bcl-2
family, bcl-xL, was diminished in MDMA-treated cells,
while no changes were elicited by MDMA in the levels of
the pro-apoptotic protein bax. Similar results have been
described in neurons exposed to MDMA [11]. The fact that
MDMA diminished bcl-xL protein levels pointed out to
mitochondria as a target for its pro-apoptotic effect, since
bcl-2 family proteins have been shown to modulate the
permeabilization of mitochondrial membranes and the sub-
sequent liberation of pro-apoptotic factors such as cyto-
chrome c [20]. MDMA treatment caused the release of
cytochrome c in both cells types, as well as caspase 3
activation, thus suggesting the sequence of events already
described for other apoptotic agents: alteration of mitochon-
drial membranes through changes in bcl-2-like proteins,
release of cytochrome c and activation of effector caspases.
The previously reported role of MDMA as an inductor of
cellular oxidative stress [31], could explain these findings
because apoptosis caused by redox disruption has been
shown to happen in many instances through alterations in
mitochondria [32]. PARP is a common substrate of cas-
pases, mainly those belonging to caspase 3 family. In HSC,
apoptosis induced by MDMA was accompanied by PARP
proteolysis. On the contrary, in primary rat hepatocytes,
neither MDMA nor other apoptotic agents such as campto-
thecin and ActD/TNF-a induced the proteolysis of PARP. In
accordance with these findings, some authors find that
caspase activation induced by several apoptotic stimuli does
not result in proteolysis of PARP in hepatocytes [33,34].
We have previously described that exposure of HSC to
MDMA produces a pro-fibrogenic effect, increasing the
expression of a1(I) procollagen mRNA [14]. In the present
study, higher concentrations of the drug that reduced via-
bility of HSC by inducing programmed cell death were
used. Therefore, we can deduce from our previous and
present data that there is a double response of HSC to
MDMA exposure: induction of either fibrogenesis or pro-
grammed cell death, depending on the dose of the drug.
These responses could reflect differences between chronic
hepatotoxicity or fibrosis and acute liver failure caused by
MDMA. However, further investigation is required to
determine the correlation between our results, either in
hepatocytes or HSC, and the in vivo hepatotoxic action of
MDMA. The doses of MDMA used in our cell culture
experiments (0.5 to 5.0 mM) are significantly higher than
peak plasma levels found in animal models for the neuro-
toxic effect of MDMA (15 AM) [35], but, to our knowledge,
plasma levels of MDMA have not been determined in
animal models for MDMA-induced liver damage, and there-
fore cannot be properly compared. Interestingly, in the
aforementioned work MDMA levels in the brain have been
found to be higher than plasma levels, reaching values of
0.1–0.25 mM [35]. A similar effect could happen in other
target organs for MDMA like the liver. The study of the
mechanisms of hepatotoxicity induced by MDMA, both in
cellular and animal models, is particularly interesting due to
the key role played by the liver as the organ responsible for
detoxification.
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